Literature DB >> 17361990

Peptide probe study of the role of interaction between the cytoplasmic and transmembrane domains of the ryanodine receptor in the channel regulation mechanism.

Tomoyo Hamada1, Mark L Bannister, Noriaki Ikemoto.   

Abstract

Ryanodine receptor (RyR) mutations linked with some congenital skeletal and cardiac diseases are localized to three easily definable regions: region 1 (N-terminal domain), region 2 (central domain), and a rather broad region 3 containing the channel pore. As shown in our recent studies, the interdomain interaction between regions 1 and 2 plays a critical role in channel regulation and pathogenesis. Here we present evidence that within region 3 there is a similar channel regulation mechanism mediated by an interdomain interaction. DP15, a peptide corresponding to RyR1 residues 4820-4841, produced significant activation of [3H]ryanodine binding above threshold Ca2+ concentrations (>or=0.3 microM), but MH mutations (L4823P or L4837V) made in DP15 almost completely abolished its channel activating function. To identify the DP15 binding site(s) within RyR1, DP15 (labeled with a fluorescent probe Alexa Fluor 680 and a photoaffinity cross-linker APG) was cross-linked to RyR1, and the site of cross-linking was identified by gel analysis of fluorescently labeled proteolytic fragments with the aid of Western blotting with site-specific antibodies. The shortest fluorescently labeled band was a 96 kDa fragment which was stained with an antibody directed to the region of residues 4114-4142 of RyR1, indicating that the interaction between the region of residues 4820-4841 adjacent to the channel pore and the 96 kDa segment containing the region of residues 4114-4142 is involved in the mechanism of Ca2+-dependent channel regulation. In further support of this concept, anti-DP15 antibody and cardiac counterpart of DP15 produced channel activation similar to that of DP15.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17361990     DOI: 10.1021/bi061557f

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  5 in total

1.  Role of amino-terminal half of the S4-S5 linker in type 1 ryanodine receptor (RyR1) channel gating.

Authors:  Takashi Murayama; Nagomi Kurebayashi; Toshiharu Oba; Hideto Oyamada; Katsuji Oguchi; Takashi Sakurai; Yasuo Ogawa
Journal:  J Biol Chem       Date:  2011-08-23       Impact factor: 5.157

2.  Structural studies of inositol 1,4,5-trisphosphate receptor: coupling ligand binding to channel gating.

Authors:  Jenny Chan; Haruka Yamazaki; Noboru Ishiyama; Min-Duk Seo; Tapas K Mal; Takayuki Michikawa; Katsuhiko Mikoshiba; Mitsuhiko Ikura
Journal:  J Biol Chem       Date:  2010-09-15       Impact factor: 5.157

Review 3.  Ryanodine receptor-mediated arrhythmias and sudden cardiac death.

Authors:  Lynda M Blayney; F Anthony Lai
Journal:  Pharmacol Ther       Date:  2009-04-01       Impact factor: 12.310

4.  Structural and functional conservation of key domains in InsP3 and ryanodine receptors.

Authors:  Min-Duk Seo; Saroj Velamakanni; Noboru Ishiyama; Peter B Stathopulos; Ana M Rossi; Samir A Khan; Philippa Dale; Congmin Li; James B Ames; Mitsuhiko Ikura; Colin W Taylor
Journal:  Nature       Date:  2012-01-29       Impact factor: 49.962

5.  Expanding the clinical-pathological and genetic spectrum of RYR1-related congenital myopathies with cores and minicores: an Italian population study.

Authors:  Aurora Fusto; Denise Cassandrini; Claudio Bruno; Elena Pegoraro; Chiara Fiorillo; Valentina Codemo; Guja Astrea; Adele D'Amico; Lorenzo Maggi; Francesca Magri; Marika Pane; Giorgio Tasca; Daniele Sabbatini; Luca Bello; Roberta Battini; Pia Bernasconi; Fabiana Fattori; Enrico Silvio Bertini; Giacomo Comi; Sonia Messina; Tiziana Mongini; Isabella Moroni; Chiara Panicucci; Angela Berardinelli; Alice Donati; Vincenzo Nigro; Antonella Pini; Melania Giannotta; Claudia Dosi; Enzo Ricci; Eugenio Mercuri; Giovanni Minervini; Silvio Tosatto; Filippo Santorelli
Journal:  Acta Neuropathol Commun       Date:  2022-04-15       Impact factor: 7.578

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.